You are here: Industry Insights > Concert Pharmaceuticals

News List

Concert Pharmaceuticals announces plans for CTP-543 phase 3 trials in alopecia areata pharmaceutical-business-review
April 06, 2020
Concert Pharmaceuticals announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata pharmafocusasia
March 07, 2019
Concert Pharmaceuticals, Inc. today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata cphi-online
May 05, 2017
Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.
Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m pharmaceutical-technology
March 08, 2017
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.